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Abstract The epinephrine test has been shown to be a
powerful tool to predict the genotype of congenital long
QT syndrome (LQTS). The aim of this study was to
evaluate its role in the diagnosis and management of LQTS
in children. The test (using the Shimizu protocol) was
conducted in patients with some evidence of LQTS but in
whom clinical and management decisions were challenging
(n = 41, age 9.6 ± 3.9 years, 19 female). LQT1, LQT2,
and negative responses to epinephrine were obtained in 16,
5, and 20 subjects, respectively. LQTS gene positivity was
obtained in two subjects. Beta-blocker therapy was started
in all subjects with a positive epinephrine response
(n = 21) and in some negative responders because of their
strong LQTS phenotype (n = 10). No therapy was given to
the subset with less convincing features of LQTS who had
also responded negatively to epinephrine (n = 10). Fol-
low-up for 3.0 ± 2 years was uneventful in both manage-
ment groups. Due to the discordance with genotyping, the
epinephrine test cannot be used to diagnose genotype-
positive LQTS but when used in combination with phe-
notype assessment and genetic screening, it could enable
better management decisions.
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Introduction
Congenital long QT syndrome (LQTS) is a primary
inherited cardiac arrhythmia syndrome with an estimated
prevalence of 1:2000 [2] and an annual mortality of 1%
[11]. Various types of LQTS are associated with mutations
in genes encoding distinct cardiac ion channels or mem-
brane adaptors. The most common types, i.e., LQT1,
LQT2, and LQT3, account for 85% of genotyped cases [8].
LQTS may be dormant lifelong or may present with syn-
cope, seizures, or sudden death from polymorphic ven-
tricular tachycardia or torsades de pointes (TdP) and is one
of the leading causes of sudden cardiac death (SCD) in
children [21].
The diagnosis of LQTS has traditionally relied on the
demonstration of a prolonged heart rate (HR) and a cor-
rected QT interval (QTc) as well as the use of a clinical
scoring system (Schwartz score, Keating criteria) that
incorporates surface electrocardiographic (ECG) ﬁndings
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the sensitivity of the Schwartz and Keating criteria in
identifying disease carriers has been shown to be low [8].
Although the typical LQTS cases present no diagnostic
difﬁculty, the borderline cases are more complex, requiring
the evaluation of multiple variables in addition to clinical
history and surface ECG [1]. The fact that cardiac events
are more often associated with sympathetic stimulation
(physical or emotional stress) in LQT1 than in either LQT2
or LQT3 forms the basis of the epinephrine test. Studies by
Shimizu et al. [16] and Vyas et al. [21, 22] have shown it to
be a powerful tool to predict the genotype of LQT1, LQT2,
and LQT3 syndromes. The present study was aimed at
evaluating the role of the epinephrine test in an unbiased
pediatric population with clinical suspicion of LQTS.
Materials and Methods
Study Cohort
The epinephrine test was conducted prospectively in 41
consecutive patients with clinical suspicion of LQTS
between January 2003 and May 2008. The unifying factor
in all of the subjects was a combination of clinical signs
and symptoms that made both diagnosing as well as ruling
out LQTS difﬁcult. Hence, the epinephrine test was per-
formed in addition to the routinely used tools to aid in the
diagnostic process of LQTS. The male-to-female ratio was
22:19, and age ranged from 1 to 15 years at presentation.
Study Design
The assessment of subjects for LQTS involved a historic
review, including family history, physical examination,
resting ECG, 24-hour ECG, exercise test, epinephrine test,
and LQTS genetic screening.
Emphasis was placed on the association of presenting
symptoms with physical or psychological stress; on family
history suggestive of LQTS, such as syncope, arrhythmia,
and sudden unexplained death; and the relation of symp-
toms to the previously mentioned triggers.
Standard 12-lead ECG recorded with the subject at rest
in the supine position was used to obtain baseline HR and
QTc. The QT was manually measured by averaging three
consecutive QRS complexes in precordial lead V5
(according to Shimizu et al. [16]). Bazett’s formula
(QTc = QT /HRR) was used to calculate the QTc. Resting
QTc was considered prolonged if it was C460 ms
(C450 ms in male subjects) [15].
The Schwartz score, which is derived in part from the
QTc, symptoms, and family history, was ascertained in
all subjects. Deﬁnite LQTS is deﬁned by an LQTS
score C4( B1 point = low probability of LQTS; 2–3
points = intermediate probability of LQTS; C4 point-
s = high probability of LQTS) [15].
Criteria proposed by Keating were also used to assess
the possibility of LQTS in the study cohort. According to
these criteria, individuals are affected if they are asymp-
tomatic with QTc[470 ms or if they have typical
symptoms with QTc[450 ms [10].
The QTc from exercise ECG and/or 24-h ECG was used
to gain additional diagnostic clues in some cases. Any
prolongation in QTc above baseline value in the 24-h ECG
was noted along with any rhythm disturbances [17].
Exercise test was performed using the Bruce protocol and a
QTc[450 ms at maximal exercise or at 1 min into
recovery was taken as a positive result [9].
After the clinical assessment and the epinephrine
challenge test, genetic screening for LQTS was performed
in our laboratory for genetic analysis as outlined
previously [8].
Epinephrine Test
The epinephrine test was performed using the protocol
described by Shimizu et al. [16]. A bolus intravenous
injection of epinephrine (0.1 ug/kg) was given under
monitoring. This was immediately followed by a continu-
ous infusion of epinephrine (0.1 lg/kg/min) for 5 min. A
12-lead ECG was recorded before the bolus, immediately
after the bolus administration, and at 30-s intervals during
the continuous infusion. Monitor surveillance was present
throughout the test and for at least 15 min after stopping the
infusion to monitor for the possible occurrence of TdP.
Blood pressure was also monitored at 2-min intervals. The
effect of epinephrine on the RR and QT intervals reaches
steady-state at approximately 2–3 min after the start of the
epinephrine infusion. Therefore, data representative of the
peak epinephrine effect were obtained 1–2 min after the
start of the infusion at peak HR, and data representative of
the steady-state effect were collected at 3–5 min after the
start of the infusion. According to Shimizu et al. [16], a
subject was considered to have LQT1 response if the QTc
increase in the peak phase was C35 ms and was main-
tained throughout the steady-state phase. LQT2 response
was present if the peak QTc increase of C80 ms was not
maintained in the steady-state phase. Both of these
responses were considered positive. A lack of increase of
QTc peak C35 ms was taken as a negative response.
Subjects already taking beta-blockers at the time of the
epinephrine test were instructed to stop the medication for
at least 5 half-lives before the test to avoid confounding
effects of the drug.
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Continuous variables are presented as mean ± SD and
catagoric variables as number of patients (n) and percent-
age (%). Student t test was used to compare continuous
data; v
2 Fisher’s exact test was used for catagoric data; and
p B 0.05 was considered statistically signiﬁcant.
Results
Study Population
The study group consisted of 22 male and 19 female sub-
jects of mean age 9.6 ± 3.9 years (range 1–15). The
baseline HR was 80 ± 15 bpm, and the baseline QTc was
441 ± 28 ms. Table 1 lists the phenotypic characteristics
of the male and female subjects. None of the variables were
statistically different between sexes.
Historic Review
The majority of subjects (n = 30 [73%]) were symptom-
atic at presentation. Syncope (including near-drowning)
and presyncope together formed the most common group,
with 27 subjects (66%) initially seeking medical attention
for this reason. The other less commonly reported symp-
toms were palpitations (n = 1 [2%]), ‘‘absence’’ seizure-
like episodes (n = 1 [2%]), and out-of-hospital cardiac
arrest due to ventricular ﬁbrillation (VF) (n = 1 [2%]). Of
the 11 (27%) asymptomatic subjects, an incidental obser-
vation of prolonged QTc was made in 7 (17%), whereas 4
(10%) were thought to have LQTS based on suspicious
family history. Figure 1 shows the frequency of the pre-
senting symptoms in the study cohort. Family history was
positive for SCD in two (5%) families, arrhythmia (VF
and/or documented TdP) in two (5%) families, and unex-
plained syncope in two (5%) families.
QTc and Clinical Scoring
The baseline QTc ranged from 380 to 502 ms
(441 ± 28 ms). Thirteen (32%) subjects, 8 (61%) of whom
were symptomatic, had a signiﬁcant QTc prolongation at
baseline. Of the 26 subjects who had a 24-h ECG record-
ing, 23 (88%) had a documented QTc prolongation, espe-
cially with higher HRs. Exercise test was positive in 23
(68%) of 34 subjects who underwent the test. No signiﬁ-
cant arrhythmias were noted during 24-h ECG monitoring
and the exercise tests. In this study cohort, 18 (44%) sub-
jects had a Schwartz score B1; 22 (54%) had a score of 2–
3; and 1 (2%) had a score of 4. The reason for suspicion of
LQTS in subjects with a Schwartz score B1 was unex-
plained syncope in eight subjects, exercise-related com-
plaints of presyncope or palpitations in a setting of
borderline QTc (440–460 ms) in ﬁve subjects, observation
of borderline QTc in two subjects during follow-up for
Kawasaki disease and pectus excavatum, respectively, and
highly suspicious family history in three subjects. Keating
criteria positivity was obtained in 10 (24%) subjects.
Response to Epinephrine
Based on the changes in QTc with epinephrine adminis-
tration, the subjects were divided into three groups. Sixteen
(39%) subjects had a QTc peak increase C35 ms, which
was maintained at steady-state (LQT1 response, group 1); 5
Table 1 Phenotypic characteristics of the study population
Phenotypic characteristics Male
(n = 22)
Female
(n = 19)
Age at presentation in years
(mean ± SD)
8.8 ± 3.9 10.5 ± 3.5
Age group in years (%)
5 6 (27) 1 (5)
6–10 9 (41) 8 (42)
[10 7 (32) 10 (53)
No. symptomatic at presentation (%) 15 (68) 15 (79)
No. incidental ﬁnding of prolonged
QTc (%)
4 (18) 3 (16)
No. family history leading to
suspicion of LQTS (%)
3 (14) 1 (5)
Baseline HR in bpm (mean ± SD) 77 ± 17 84 ± 13
Baseline QTc in ms (mean ± SD) 437 ± 33 447 ± 23
Average Schwartz score (range) 1.4 (0–3) 1.9 (0–4)
No. Keating criteria positivity (%) 6 (27) 4 (21)
bpm beats per minute, QTc corrected QT interval
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Fig. 1 Frequency of presenting symptoms in the study population
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123(12%) subjects had a QTc peak increase C80 ms, which
was not maintained at steady-state (LQT2 response, group
2); and 20 (49%) subjects did not show a QTc peak
increase C35 ms (negative response, group 3). The aver-
age increase in QTc as well as in HR from baseline values
was higher for the LQT1 and LQT2 response groups than
for the negative response group (Table 2). Table 2 lists the
clinical parameters of the LQT1 response, LQT2 response,
and negative response groups.
Complications During Epinephrine Test
Two (5%) subjects belonging to group 3 with baseline QTc
of 450 and 479 ms, respectively, experienced nonsustained
ventricular tachycardia (NSVT) during the test.
Genetic Screening
Based on clinical suspicion, genetic screening for LQTS
was performed in 39 of the 41 subjects. A 14-year-old
female subject with history of an episode of syncope
(normal ECG, QTc 439 ms) demonstrated classic hyper-
ventilation during the epinephrine test and had a negative
response to the test. She was diagnosed with hyperventi-
lation syndrome. A 9-year-old male subject who was
screened for LQTS due to the sudden death of his father
was not found to have any clinical indicators of LQTS
(asymptomatic, normal ECG, QTc 428 ms, and negative
epinephrine response). Hence, the previously mentioned
two subjects did not undergo genetic analysis for LQTS.
The LQTS genes tested were KCNQ1 (LQT1, n = 39),
KCNH2(LQT2,n = 39),SCN5A(LQT3,n = 25),KCNE1
(LQT5, n = 20), KCNE2 (LQT6, n = 19), and KCNJ2
(LQT7, n = 1) (Fig. 2). Only when appropriate (based on
clinical history), subjects underwent screening for RYR2
and CASQ2 (genes associated with catecholaminergic
polymorphic ventricular tachycardia or CPVT). Pathogenic
KCNQ1 mutations were shown in two subjects. A KCNQ1-
gene mutation was detected (p.Phe193Leu) in a 15-year-old
female subject with recurrent syncope, baseline QTc
440 ms, Schwartz score 1, and LQT1 response to epineph-
rine. A 9-year-old female subject with syncope, baseline
QTc 470 ms, Schwartz score 3, negative epinephrine
response,andinitiallynegativegeneticscreeningunderwent
further extensive DNA analysis using multiplex ligation-
dependent probe ampliﬁcation (MLPA), which detected a
large KCNQ1 deletion mutation of exons 2–10.
Furthermore, two mutations of questionable pathoge-
nicity were found in a 3-year-old male subject with syn-
cope, baseline QTc 427 ms, Schwartz score 1, and negative
Table 2 Comparison of clinical
parameters of the three subject
groups based on response to the
epinephrine challenge test
bpm beats per minute,
QTc corrected QT interval
Parameters LQT1
response
(n = 16)
LQT2
response
(n = 5)
Negative
response
(n = 20)
Baseline HR (bpm) 74 ± 10 78 ± 11 87 ± 18
Baseline QTc (ms) 442 ± 25 435 ± 40 443 ± 30
Increase in HR with epinephrine (bpm) 29 ± 93 2 ± 92 0 ± 10
Increase in QTc with epinephrine (ms) 105 ± 37 100 ± 11 34 ± 19
No. Schwartz score[3 (%) 0 (0) 1 (20) 0 (0)
No. Schwartz score 2–3 (%) 9 (56) 2 (40) 11 (55)
No. Schwartz score 1 (%) 7 (44) 2 (40) 9 (45)
No. Keating criteria positivity (%) 2 (13) 1 (20) 7 (35)
No. 24-h ECG positivity (%) 9 (60) 3 (60) 11 (55)
No. exercise test positivity (%) 13 (81) 3 (60) 7 (35)
No. genetic test positive (%) 1 (6) 0 1 (5)
39(100%) 39(100%)
25(64%)
20(51%)
19(49%)
1(3%)
4(10%)
2(5%)
0
10
20
30
40
KCNQ1 KCNH2 SCN5A KCNE1 KCNE2 KCNJ2 RYR2 CASQ2
Number of subjects
Fig. 2 Number of subjects screened for the different LQTS and
CPVT genes: KCNQ1-LQT1 gene, KCNH2-LQT2 gene, SCN5A-
LQT3 gene, KCNE1-LQT5 gene, KCNE2-LQT6 gene, KCNJ2-LQT7
gene, RYR2 and CASQ2-CPVT genes
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123epinephrine response. The ﬁrst is a variant c.3331-9-8
delGT in intron 14 of the KCNH2 gene, and the other is
mutation c.895T[A in the SCN5A gene.
A 10-year-old female subject with a near-drowning
episode and a previous history of Wilms’ tumour was noted
to have a slightly abnormal methylation of the L1T1 gene,
a gene associated with Beckwith–Wiedemann syndrome.
She had a LQT1 type epinephrine response, and her LQTS
screening (LQT1, 2, 3, 5 and 6) was negative.
An 8-year-old female subject with Turner syndrome,
prolonged QTc on routine cardiac evaluation, and LQT1-
type epinephrine response was also negative for LQTS
screening (LQT1, 2, 3, 5, and 6).
Management and Follow-Up
Beta-blocker therapy was instituted to all subjects with a
positive epinephrine response (group1 ? group 2, n = 21)
and to 50% of the negative responders (n = 10) based on
persisting suspicion of LQTS (gene positivity in one
symptomatic subject, two mutations of unknown pathoge-
nicity in one symptomatic subject, signiﬁcantly abnormal
ECG with prolonged QTc in ﬁve subjects, and ventricular
ectopic activity and/or NSVT in three subjects). The
rationale for no therapy in 50% of the negative responders
(n = 10) was the ‘‘virtual’’ ruling out of LQTS by a neg-
ative epinephrine response, particularly in combination
with a less convincing phenotype. Beta-blockers were
either withdrawn after the epinephrine test response (four
subjects), or the initial decision for no therapy was main-
tained after the test (n = 6, including the subject with VF
who was implanted with an implantable cardiac deﬁbril-
lator (ICD) because his genetic screening for LQTS and
CPVT was negative).
Mean baseline QTc and Schwartz scores of the therapy
group (446 ± 29 and 1.7 ± 1.1, respectively) were higher
than those of the nontherapy group (426 ± 28 and
1.4 ± 1.0, respectively). All of the patients undergo regular
pediatric cardiology clinic follow-up (maximum 8 years;
mean 3.0 ± 2 years; age 12.8 ± 3.7 years) with periodic
24-h ECG monitoring and exercise tests. The subjects in
the therapy group were compliant and responded well to
treatment. They had no problems related to beta-blockers
side effects. The subjects in the nontherapy group were free
of LQTS-related cardiac events.
Discussion
The LQTS phenotype is highly variable, ranging from
asymptomatic ECG repolarisation abnormalities to sudden
death. Male sex, a history of syncope at any time during
childhood, and a QTc duration[500 ms have been shown
to be the three main risk factors for life-threatening cardiac
events in children with LQTS who are\12 years of age
[6]. Early identiﬁcation of patients at risk and a reliable
diagnosis of LQTS become extremely important for
effective management of these children. Although diag-
nostic tools—such as clinical scoring, provocation tests,
and molecular screening—have all contributed to identi-
fying LQTS in patients, a ‘‘gold-standard’’ diagnostic tool
is still lacking for this challenging group of disorders.
Although molecular diagnosis of LQTS, which is not
always similar to conﬁrmation, has now become com-
mercially available, only approximately 70% of families
with a suspected channelopathy are noted, whereas the
remaining families with a strong clinical probability of
LQTS will have a negative genetic test result [18–20].
Furthermore, it has been shown that a negative genetic test
in a subject with clinical LQTS (i.e., genotype-negative/
phenotype-positive LQTS) does not provide a basis to
discard the diagnosis [5].
In asymptomatic LQTS patients with normal repolari-
sation values (silent mutation carriers), the clinical scoring
loses efﬁcacy. Provocation tests, such as the epinephrine
test, are proposed to have added value as an additional
diagnostic and predictive tool in this setting. Landmark
studies on the value of epinephrine testing in the diagnosis
of LQTS have been published by Shimizu et al. [16] and
Vyas et al. [21, 22]. During the epinephrine test, QTc
prolongation at the peak of epinephrine, which is main-
tained at steady state conditions of epinephrine, has been
described in patients with LQT1. Epinephrine prolongs the
QTc more dramatically at the peak of epinephrine infusion
in LQT2 patients, but the QTc returns to baseline levels at
steady-state conditions. A much milder prolongation of
QTc at the peak of epinephrine has been described in LQT3
patients and controls, and it returns to the baseline levels at
steady-state conditions. Based on the pathophysiology of
these genotypes, this response is reasonably well under-
stood [16]. Thus the epinephrine test in patients suspected
with LQTS was proposed to assist in the identiﬁcation of
affected patients, to allow for the prediction of the genetic
type, and to guide the order of molecular DNA analysis.
Hence, we used the test as a tool to guide clinical decision
making in a pediatric cohort with a suspicious LQTS
phenotype.
Recently, Magnano et al. showed that catecholamines,
such as epinephrine and isoproterenol, are associated with
signiﬁcant QTc prolongation also in healthy subjects [13],
which in turn questions the diagnostic efﬁcacy of the epi-
nephrine test. The results of the present study show epi-
nephrine test sensitivity and speciﬁcity of 50 and 61%,
respectively, for the LQT1 response subset. The positive
predictive value for subsequent identiﬁcation of a positive
genotype in the major potassium channel genes (in
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123particular LQT1) is 6%, and the negative predictive value
for (virtually) ruling it out is 96%. The lower test values.
compared with the study by Vyas et al. [22]. may be
explained by the difference in the referral pattern between
the two institutions as well as in the age group of the
subjects.
Based on recent advances in LQTS genotyping, it was
hypothesized that approximately 70% of subjects with a
positive epinephrine response would show LQTS gene
positivity. Contrary to expectations, only 5% (1 of 21) of
positive responders did have an underlying LQTS muta-
tion. The paradox between the epinephrine test and
genotyping could possibly be attributed to the following
factors: The present study included all children with a
suspicious LQTS phenotype and did not have speciﬁc
inclusion criteria based on QTc and clinical scoring
compared with the more rigid inclusion criteria adopted
by Shimizu et al. [16] (LQTS-affected individuals were
noted on the basis of electrocardiographic diagnostic
criteria by Keating et al., including a QTc C 470 ms in
asymptomatic individuals and a QTc[440 ms for men
and[460 ms for women associated with one or more of
the following: stress-related syncope, documented TdP, or
family history of early SDC). This paradox may also
reﬂect differences in our population or minor differences
in the infusion protocols. Moreover, on pursuing genetic
testing with the MLPA technique, we identiﬁed a deletion
mutation in an LQT1 patient with an impressive LQTS
phenotype. There could be other such cases eluding
genotype at the present time, thus accounting for the
lower-than-expected positive yield.
However, the response to epinephrine has enabled the
management of this challenging group of patients. It should
once again be highlighted here that the study cohort, which
was comprised of young patients with a constellation of
signs and symptoms suggestive but not conclusive of
LQTS, made diagnostic and management decisions difﬁ-
cult. The subjects who responded positively to epinephrine
were considered likely to beneﬁt from beta-blockers and
hence were started on therapy. A diagnosis of LQTS was
‘‘virtually’’ ruled out in 50% of negative responders based
on their response to epinephrine combined with their less
convincing clinical phenotype; hence, they were not com-
menced on beta-blockers.
The therapy and nontherapy groups were both followed-
up at regular intervals. Although the subjects using beta-
blockers responded well to treatment, the subjects in the
no-therapy group did not show any LQTS-related cardiac
events warranting inclusion of therapy. Being able to rule
out LQTS with conﬁdence is important because a positive
diagnosis brings with it enormous emotional, social, and
economic consequences. Uncertainty of the diagnosis leads
to anxiety for both families and caregivers [7]. This study
shows that the epinephrine test together with clinical
scoring and genetic screening helps in making a more
conﬁdent management decision.
An abnormal exercise test has been shown to have a
high correlation with LQT1 subtype [9]. In the current
study, LQT1 responders had a high concordance of 81%
with exercise test positivity; LQT2 responders had a 60%
concordance; and negative responders had a low con-
cordance of 35% (Table 2). Although it could be argued
that both the exercise and epinephrine tests appear to
produce similar results and could be performed mutually
exclusively, it is also evident that both tests have some
value in this difﬁcult situation of positively diagnosing
suspicious LQTS. The exercise test is noninvasive, rel-
atively easier to perform, and may be useful to expose a
prolonged QTc in borderline cases, whereas the epi-
nephrine test might prove a better tool to rule LQTS in
suspicious cases.
The numerous mutations in the LQTS-associated genes
reported to date are point mutations or small insertions and
deletions in coding regions or at splice junctions. It has
recently been shown that large, multiple-exon deletions and
duplications in cardiac ion channel genes account for a
noteworthy proportion of LQTS cases [3, 12]. In the
present study, MLPA DNA analysis eventually identiﬁed a
large pathogenic KCNQ1 gene deletion in an 8-year-old
female subject.
The therapeutic options of this genotypically and
phenotypically heterogeneous disease include beta-block-
ade, mexiletine, pacemakers, ablation of the left stellate
ganglion, ICD implantation, in addition to sports restric-
tions and avoidance of medications that lengthen repo-
larisation [4]. ICD therapy is reserved for high-risk
patients unlikely to respond to who have failed beta-
blocker therapy. All of the subjects in this study who
were in the therapy group responded adequately to beta-
blockers. Device implantation was not warranted in any
of the subjects except in the infant diagnosed with idio-
pathic ventricular ﬁbrillation.
The epinephrine test is generally a safe test with a low
rate of complications. Ventricular extrasystoles, ventricular
bigeminy, NSVT, and spontaneously terminating TdP have
been reported. The present study shows the test to be safe
in children with NSVT, which was noted in only 2 (5%)
subjects.
Study Limitations
The study is limited by the lack of a control group. It would
be ideal to compare the responses to epinephrine in (more
deﬁnite) pediatric LQTS patients with those in healthy
children, but the ethical issues involved in such a study are
paramount.
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123Conclusion
Congenital LQTS in children is a potentially life-threat-
ening disease. Although effective therapeutic strategies for
LQTS have evolved, it is still challenging at times to make
the appropriate diagnostic and management decisions in
suspected cases. It is clear that the epinephrine test cannot
be used to diagnose genotype-positive LQT, but when used
in combination with phenotype assessment and genetic
screening, it could enable better management decisions.
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